Translation of "Claudication" in German

The population was old and suffered from intermittent claudication.

Intermittent claudication is the cramp-like pain in your legs when you walk and is caused by insufficient blood supply in your legs.

Intermittent claudication is caused by plaque formation within the leg arteries.

This can relieve headaches and intermittent claudication.

Classic symptom is the so-called spinal claudication.

Pletal is a medication used for reducing attacks of intermittent claudication.

Glycine Propionyl L-Carnitine (GPLC) is used to alleviate intermittent claudication and blood flow issues.

This includes diseases such as intermittent claudication, varicose veins, arteriosclerosis, circulatory disorders or thromboses.

Pletal Cilostazol Pletal is a medication used for reducing attacks of intermittent claudication.

On 22 March 2013 the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and affects the ability to walk - should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.

The Committee concluded that the benefit-risk balance of nicergoline containing products is not favourable pursuant to Article 116 of Directive 2001/83/EC for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia), for ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II), for ancillary treatment of Raynaud's syndrome, for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin, for acute retinopathies of vascular origin and for prophylaxis of migraine headache.

Overall, the group was of the view that for a small group of patients with low risk of cardiovascular co-morbidities, limiting intermittent claudication who cannot manage initial exercise rehabilitation, or who are unsuitable for revascularisation, this drug may have a role.

Cilostazol should be initiated by physicians experienced in the management of intermittent claudication (see also section 4.4).

The primary endpoint in the nine efficacy trials (called mid-term trials) was maximum walking distance (absolute claudication distance - ACD), measured by exercise treadmill testing.

The efficacy of cilostazol has been evaluated in 14 clinical trials which enrolled more than 4000 intermittent claudication (IC) patients.

The experts were of the view that cilostazol has a beneficial effect in patients with limiting intermittent claudication who cannot manage an exercise program in getting such patients over “the first hurdle” that would then allow them to continue progression of their walking distance through exercise.

The Committee concluded that the benefit-risk balance of cilostazol products for the improvement of the maximal walking distance and maximal pain-free walking distances in patients with intermittent claudication (IC), who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II) remains positive under normal conditions of use, subject to restrictions, warning, changes to the product information and risk minimisation measures agreed.